EGRABINS1

CompletedPhase 2

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

The Effect of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist on Cerebral Blood Flow Velocity in Non-Stroke Volunteers (EGRABINS1)

Lead sponsor

Christina Kruuse

Assets

Exenatide / GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Actual enrollment

Study population

Healthy volunteers

Eligibility highlights

Primary endpoint

•Changes in the mean flow velocity in the middle cerebral arteries (mean flow velocity middle cerebral artery, cortical oxygenation nirs)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02838589

Org study IDH-16022532

Secondary ID2016-001221-14

Timeline

Milestones

Study first posted2016-07-20estimated

Last update posted2017-02-07estimated

Study start2016-08 (month precision)

Primary completion2017-02actual (month precision)

Study completion2017-02actual (month precision)

Assets

Investigational agents

Exenatide GLP-1 / incretin class catch-all

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Person ≥ 50 years of age

•Has given written informed consent

Exclusion criteria

•Intracerebral haemorrhage

•Subdural / epidural hemorrhage

•subarachnoid haemorrhage

•previously major structural damage to the brain (eg. sequelae after large stroke or brain surgery)

•Diabetes type 1

•Diabetes type 2

•Known atrial fibrillation

•> 50% stenosis of internal carotid

•Known allergy to GLP-1 receptor agonists

•Hepatic impairment (ALT> 3 x upper normal limit)

•Renal impairment (eGFR <30 ml / min)

•Inflammatory bowel disease

•Previous pancreatitis

•Heart failure (NYHA class 3-4)

•Pregnancy or lactation

•Patient not expected to co-operate to the investigations

•Visualization of the middle cerebral artery bilaterally by transcranial doppler not possible

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Other (unclassified)

Cardiometabolic biomarkers

3 endpoints

Secondary/protocol endpoint

Changes in the endothelial reactivity measured by non-invasive pletysmography.

Time frame:3 hours

change from baseline, improvement

Secondary/protocol endpoint

Changes in the endothelial/inflammatory biomarkers in blood.

Time frame:3 hours

change from baseline, improvement

Secondary/protocol endpoint

Changes in the ankle-brachial index.

Time frame:3 hours

change from baseline, improvement

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination .

Time frame:Up till 3 hours

change from baseline, descriptive

componentsmean flow velocity middle cerebral artery, cortical oxygenation nirs

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial.
Frontiers in aging neuroscience2022 (year)PMID36636739doi:10.3389/fnagi.2022.899389via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.